Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques

• DOI: 10.1038/s41541-022-00477-x
• Publication Date: 2022-05-18T10:02:54Z
• Authors: John D. Ventura; Joseph P. Nkolola; Abishek Chandrash...; Erica N. Borducchi; Jinyan Liu; Noe B. Mercado; David L. Hope; Victoria M. Giffin; Katherine McMahan; Romas Geleziunas; Jeffrey P. Murry; Yunling Yang; Mark G. Lewis; Maria G. Pau; Frank Wegmann; Hanneke Schuitemaker; Emily J. Fray; Mithra R. Kumar; Janet D. Siliciano; Robert F. Siliciano; Merlin L. Robb; Nelson L. Michael; Dan H. Barouch
• Keywords: Discontinuation; Modified vaccinia Ankara

Developing an intervention that results in virologic control following discontinuation of antiretroviral therapy (ART) is a major objective HIV-1 cure research. In this study, we investigated the therapeutic efficacy vaccine consisting adenovirus serotype 26 (Ad26) and modified vaccinia Ankara (MVA) with or without SIV Envelope (Env) gp140 protein alum adjuvant combination TLR7 agonist vesatolimod (GS-9620) 36 ART-suppressed, SIVmac251-infected rhesus macaques. Ad26/MVA vaccination led to robust humoral cellular immune responses, Env boost increased antibody responses. Following ART, was observed 5/12 animals each group, compared 0/12 sham group. These data demonstrate but no clear additional benefit adding boost. SIV-specific responses correlated control. Our findings show partial ART SIV-infected